Fintel reports that on November 4, 2025, Guggenheim maintained coverage of Pyxis Oncology (NasdaqGS:PYXS) with a Buy recommendation. Analyst Price Forecast Suggests 60.63% Upside As of October 30, ...
BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat cancers, ...
Tang Capital Partners Lp has filed a 13G form with the SEC disclosing ownership of 1,981,426 shares of Pyxis Oncology Inc (PYXS). This represents 5.6% of the company. Pyxis Oncology had cash and cash ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the ...
Pyxis Oncology ( (PYXS)) has provided an announcement. On December 18, 2025, Pyxis Oncology reported positive preliminary Phase 1 data for its first-in-concept antibody-drug conjugate MICVO in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results